NasdaqCM - Nasdaq Real Time Price USD

Xenetic Biosciences, Inc. (XBIO)

Compare
4.3199 +0.0799 (+1.88%)
At close: January 21 at 4:00:00 p.m. EST
4.3100 -0.01 (-0.23%)
After hours: January 21 at 4:01:23 p.m. EST
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for XBIO

Recent News: XBIO

View More
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
ACCESS Newswire last month
Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform

Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
ACCESS Newswire last month
Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program

Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program
ACCESS Newswire last month
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis
ACCESS Newswire last month
Xenetic Biosciences Third Quarter 2024 Earnings: Misses Expectations

Xenetic Biosciences Third Quarter 2024 Earnings: Misses Expectations
Simply Wall St. 2 months ago
Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results

Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results
ACCESS Newswire 2 months ago

Xenetic Biosciences: Q3 Earnings Snapshot
Associated Press Finance 2 months ago
Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models

Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models
ACCESS Newswire 2 months ago
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
ACCESS Newswire 2 months ago
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024

Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
ACCESS Newswire 2 months ago
Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform

Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform
ACCESS Newswire 3 months ago
View More

Related Tickers

VTVT vTv Therapeutics Inc.
13.97
+2.38%
 
RLYB Rallybio Corporation
0.8940
+2.15%
 
ATHE Alterity Therapeutics Limited
3.4900
+1.16%
 
AKTX Akari Therapeutics, Plc
1.2900
+6.61%
 
IMMP Immutep Limited
1.9100
-1.04%
 
KTTA Pasithea Therapeutics Corp.
2.5250
+1.81%
 
CLSD Clearside Biomedical, Inc.
0.9221
-0.84%
 
ADIL Adial Pharmaceuticals, Inc.
0.9725
-1.77%
 
SCPS Scopus BioPharma Inc.
0.0003
0.00%
 
LIXT Lixte Biotechnology Holdings, Inc.
2.3835
+2.30%